NEW YORK (TheStreet) -- Approval for the Keystone pipeline was pushed down the road again Tuesday, but this time it took an important Senate effort for incentives on energy efficiencies with it.

A bill that's been roaming around the floor of the Senate since 2011, promising incentives for efficient "smart grid" electric systems, got scuttled as partisan bickering over Keystone wouldn't allow the bill to get a vote. Democrats blamed Republicans and the Republicans blamed Democratic leadership, but the bottom line is that a bill with bi-partisan support, that would have helped everyone, failed to get passed due to the political football that Keystone has become. There hasn't been an energy bill that's been voted through by Congress since 2007.

And it's starting to look like the Canadians are running out of patience. At a conference of Canadian oil producers, delegates expressed dismay at the delays of getting a final dispensation for Keystone.

TransCanada (TRP), the majority stakeholder in the Keystone pipeline, has proposed a different pipe route for moving increasing quantities of oil sands production from the Athabasca. Their idea is an $11 billion pipeline from Western Canada moving east to New Brunswick called the "Energy East" pipeline. A fully Canadian pipe accessing Canadian ports obviously won't need U.S. approval to construct. It seems clear that TransCanada is making new plans to keep up with ramping oil sands production, regardless of whether Keystone is ultimately approved.

What also seems clear is that the lack of approval of Keystone won't slow down Canadian production of oil sands assets much. Of the Canadian oil stocks in the Athabasca, I particularly like undervalued Cenovus (CVE).

If you liked this article you might like

Keystone Pipeline Critics Appealing to GOP's Favorite Issues in Nebraska Battle

TransCanada to Decide on Keystone XL Pipeline Investment by December

Nobody's Interested: TransCanada Facing New Keystone XL Issue

Energy Transfer's Pipeline Spill Problem Is Causing It Another Headache

Week in Review: Stocks See Worst Week Since Election as Trump Dealt Setback With Health-Care Bill